rc98
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 15, 2020 (NCT04190823)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Insulin receptorAGONIST
INSR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05514158 | Phase 1 | Oct 30, 2022 | RemeGen |
| NCT04190823 | Phase 1 | Jan 15, 2020 | RemeGen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RemeGen | For profit | 2 | 2 | 1 | 2020 |
1 organizations
Page 1 / 1